TY - JOUR
AU - Anh Bui
AU - Christina Kong
AU - Nicole Kelly
AU - S Rathinam
AU - John Gonzales
AU - Radhika Thundikandy
AU - Anuradha Kanakath
AU - Bala Murugan
AU - R Vedhanayaki
AU - Lyndell Lim
AU - Eric Suhler
AU - Hassan Al-Dhibi
AU - Thuy Doan
AU - Nisha Acharya
AU - First-line Group
AB - <p>This subanalysis from the First-line Antimetabolites as Steroid-sparing Treatment Trial found no significant difference in the time to achieve a corticosteroid-sparing dosage of prednisone for patients with noninfectious uveitis treated with methotrexate versus mycophenolate mofetil.</p>

BT - Ophthalmology
DA - 2022 Jan 24
DO - 10.1016/j.ophtha.2022.01.020
J2 - Ophthalmology
LA - eng
N2 - <p>This subanalysis from the First-line Antimetabolites as Steroid-sparing Treatment Trial found no significant difference in the time to achieve a corticosteroid-sparing dosage of prednisone for patients with noninfectious uveitis treated with methotrexate versus mycophenolate mofetil.</p>

PY - 2022
T2 - Ophthalmology
TI - Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.
SN - 1549-4713
ER -